Cellectar registers Phase 3 trial comparing iopofosine I 131 to R-CD in Waldenstrom'sAug 14Trial updateCellectar Biosciences, Inc.
Cellectar reports Q2 2026 results, advances Phase 3 WM trial toward mid-2027 filingAug 13Quarterly updateCellectar Biosciences, Inc.
Cellectar shareholders back share plan increase and warrant exercise voteJul 10PeopleCellectar Biosciences, Inc.
Sign in